

26. A pharmaceutical composition comprising a compound of any of claims 1-25 or a stereoisomer, tautomer, solvate, prodrug or salt thereof and a pharmaceutically acceptable carrier, diluent or excipient.
27. Use of a compound of any of claims 1-25 or a stereoisomer, tautomer, solvate, prodrug or salt thereof in therapy.
28. Use of a compound of any of claims 1-25 or a stereoisomer, tautomer, solvate, prodrug or salt thereof in the treatment of an inflammatory disease.
29. Use of a compound of any of claims 1-25 or a stereoisomer, tautomer, solvate, prodrug or salt thereof for the preparation of a medicament for the treatment of an inflammatory disease.
30. A compound of any of claims 1-25 or a stereoisomer, tautomer, solvate, prodrug or salt thereof for use in the treatment of an inflammatory disease.
31. The use or compound of any of claims 28-30 or a stereoisomer, tautomer, solvate, prodrug or salt thereof, wherein the inflammatory disease is asthma.
32. A method of preventing, treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient, comprising administering to the patient a therapeutically effective amount of a compound of any of claims 1-25 or a stereoisomer, tautomer, solvate, prodrug or salt thereof.
33. The method of claim 32, wherein the disease or condition is asthma.
34. The method of claim 32, wherein the Janus kinase is JAK1.